Hematological Neoplasms

CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) is a form of cellular immunotherapy that involves genetically modifying a patient’s T cells to express a specific chimeric antigen receptor (CAR), inducing an anti-tumor response.

BCMA (B-cell maturation antigen, also known as CD269 or TNFRSF17) has become a major target for CAR-T cell therapy in multiple myeloma patients.

Currently, the FDA has approved six CAR-T cell therapies.

March 15,2024,the FDA Oncologic Drugs Advisory Committee (ODAC) held a full-day meeting to review the benefit/risk profiles of Abecma from BMS/Bluebird Bio and Carvykti from Johnson & Johnson/Legend Biotech, two BCMA CAR-T therapies for frontline treatment.

Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) has shown activity in treating relapsed or refractory multiple myeloma

Zevorcabtagene autoleucel is the fifth CAR-T cell therapy approved for marketing in China, following FOSUN Kite’s Axicabtagene Ciloleucel Injection, JW THERAPEUTICS’ Relmacabtagene autoleucel, IASO Bio’s Equecabtagene Autoleucel, and Juventas’ Inaticabtagene Autoleucel Injection.

In recent years, chimeric antigen receptor T (CAR-T) cell therapy, as a highly promising immunotherapy, has profoundly transformed the treatment landscape of hematological malignancies.

In recent years, clinical trials have demonstrated the remarkable efficacy of CAR-T therapy in relapsed/refractory MM (RRMM). Currently, two BCMA-targeted CAR-T therapies, idecabtagene vicleucel (ide-cel; trade name: Abecma) and ciltacabtagene autoleucel (cilta-cel; trade name: Carvykti), have been approved by the FDA in 2021 and 2022, respectively, for the treatment of RRMM in patients who have received at least five prior lines of therapy.

On March 2-3, 2024, the 7th Beijing Thrombosis and Hemostasis Conference and the 5th Beijing Hematologic Malignancies and Immunology Summit, hosted by the National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, was successfully held in Beijing.

In the not-too-distant future, CAR-T cell therapy products for multiple myeloma will gradually be launched and quickly enter the clinic, which is good news.